A genetically engineered single-chain FVTNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor
Authors:
- 1 August 1995
- journal article
- Published by Elsevier in Molecular Immunology
- Vol. 32 (12) , 873-881
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Single‐chain antibody variable region‐targeted interleukin‐2 stimulates T cell killing of human colorectal carcinoma cellsImmunology & Cell Biology, 1994
- Recombinant Bifunctional Molecule FV/IFN-γ Possesses the Anti-Tumor FV as Well as the Gamma Interferon ActivitiesCancer Biotherapy, 1993
- Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.Journal of Experimental Medicine, 1991
- Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignanciesEuropean Journal of Cancer and Clinical Oncology, 1989
- Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic StudyJNCI: Journal of the National Cancer Institute, 1988
- Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.Journal of Experimental Medicine, 1987
- Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1Nature, 1986
- Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genesJournal of Molecular Biology, 1986
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985
- Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude miceInternational Journal of Cancer, 1984